ReviewBlood2016
Discordant bone marrow involvement in non-Hodgkin lymphoma.
Review in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Discordant lymphoma consisting of splenic marginal zone lymphoma and diffuse large B-cell lymphoma in a hepatitis B virus carrier suggests virus-associated lymphomagenesis.Journal of clinical and experimental hematopathology : JCEH · 2026Article
- Common Lymphoma in an Uncommon Location.American journal of hematology · 2025Article
- Discordant lymphoma characterized by the coexistence of diffuse large B-cell lymphoma in the brain and mantle cell lymphoma in the colon, rectum, and bone marrow.Brain tumor pathology · 2025Article
- [Chinese expert consensus on the application of flow cytometry in the diagnosis and detection of minimal residual disease in B-cell non-Hodgkin lymphoma (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Chinese expert consensus on flow cytometric detection of hematological malignant cells in tissue samples.Journal of the National Cancer Center · 2025Article
- Prognostic impact of concordant and discordant bone marrow involvement on diffuse large B-cell lymphoma.Translational cancer research · 2024Article
- Article
- A comprehensive review of the role of bone marrow biopsy and PET-CT in the evaluation of bone marrow involvement in adults newly diagnosed with DLBCL.Frontiers in oncology · 2024Review
- Article
- Case Report: Effects of multiple myeloma therapy on essential thrombocythemia and vice versa: a case of synchronous dual hematological malignancy.Frontiers in oncology · 2023Article
- Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms.Frontiers in oncology · 2023Article
- Sinonasal lymphoma: A primer for otolaryngologists.Laryngoscope investigative otolaryngology · 2022Review
- Diffuse large B-cell lymphoma: morphologic and immunohistochemical analysis of bone marrow for staging, with emphasis on lymphoid aggregates.International journal of clinical and experimental pathology · 2022Article
- Genetic evolution ofHaematologica · 2021Article
- Application of CD54 in diagnosing bone marrow involvement by using flow cytometry in patients with diffuse large B-cell lymphoma.BMC cancer · 2021Article
- Biopsy remains indispensable for evaluating bone marrow involvement in DLBCL patients despite the use of positron emission tomography.International journal of hematology · 2021Article
- Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-Cell Lymphoma.Cancers · 2020Article
- Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse.Blood cancer journal · 2019Article
- Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study.American journal of clinical pathology · 2018Article
- How I manage patients with relapsed/refractory diffuse large B cell lymphoma.British journal of haematology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A discordant lymphoma occurs where 2 distinct histologic subtypes coexist in at least 2 separate anatomic sites. Histologic discordance is most commonly observed between the bone marrow (BM) and lymph nodes (LNs), where typically aggressive lymphoma is found in a LN biopsy with indolent lymphoma in a BM biopsy. Although the diagnosis of discordance relied heavily on histopathology alone in the past, the availability of flow cytometry and molecular studies have aided the identification of this entity. The true prevalence and clinical ramifications of discordance remain controversial as available data are principally retrospective, and there is therefore little consensus to guide optimal management strategies. In this review, we examine the available literature on discordant lymphoma and its outcome, and discuss current therapeutic approaches. Future studies in discordant lymphoma should ideally focus on a large series of patients with adequate tissue samples and incorporate molecular analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.